Publications by Professor Olaf Heidenreich - ePrints

Browsing publications by Professor Olaf Heidenreich.

Newcastle Authors	Title	Year
Dr Hayden Bell Dr Helen Blair Samantha Jepson Gosling Dr Martin Galler Dan Astley et al.	Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia	2024
Dr Sarah Fordham Dr Wei-Yu Lin Dr Helen Blair Dr Claire Elstob Dr Hayden Bell et al.	Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia	2023
Dr Paul Sinclair Dr Ruth Cranston Prahlad Raninga Joanna Cheng Rebecca Hanna et al.	Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia	2023
Dr Hayden Bell Dr Helen Blair Mankaran Singh Professor Anthony Moorman Professor Olaf Heidenreich et al.	Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia	2023
Dr Jose Luis Marin-Rubio Dr Maria Duenas Fadic Dr Tiaan Heunis Dr Abeer Dannoura Dr Joe Inns et al.	A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia	2022
Dr Ricky Tirtakusuma Dr Katarzyna Szoltysek Professor Vasily Grinev Dr Sirintra Nakjang Dr Daniel Williamson et al.	Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia	2022
Professor Vasily Grinev Dr Sirintra Nakjang Hesta McNeill Dr Mojgan Reza Dr Natalia Martinez Soria et al.	RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia	2021
Professor Olaf Heidenreich	Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALL	2021
Mankaran Singh Dr Helen Blair Philip Berry Professor Olaf Heidenreich	Multi-drug chemotherapy dose optimisation in preclinical leukaemia models using HPLC-MS/MS	2020
Professor Olaf Heidenreich	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia	2019
Dr Helen Blair Professor Olaf Heidenreich	Subtype-specific regulatory network rewiring in acute myeloid leukemia	2019
Dr Deepali Pal Dr Helen Blair Professor Olaf Heidenreich	Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia	2019
Dr Paul Sinclair Dr Helen Blair Dr Sarra Ryan Dr Lars Buechler Joanna Cheng et al.	Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21	2018
Professor Olaf Heidenreich Professor Hermann Josef Vormoor	Epidemiology and biology of relapse after stem cell transplantation	2018
Dr Sarah Fordham Dr Helen Blair Dr Claire Elstob Professor Ruth Plummer Dr Yvette Drew et al.	Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase	2018
Patricia Garrido Castro Professor Olaf Heidenreich	The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis	2018
Professor Olaf Heidenreich Professor Hermann Josef Vormoor	The MLL recombinome of acute leukemias in 2017	2018
Dr Lynsey McKenzie Hasan Issa Sandeep Potluri Dr Helen Blair Asmida Isa et al.	The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation	2018
Dr Alex Elder Dr Simon Bomken Dr Ian Wilson Dr Helen Blair Dr Simon Cockell et al.	Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia	2017
Professor Olaf Heidenreich	MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia	2017
Yura Grabovska Professor Olaf Heidenreich	RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML	2017
Judith Weiland Dr Deepali Pal Marian Case Professor Julie Irving Dr Frida Ponthan et al.	BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance	2016
Dr Deepali Pal Professor Olaf Heidenreich Professor Hermann Josef Vormoor	Dormancy Stems the Tide of Chemotherapy	2016
Dr Lynsey McKenzie Dr Sirintra Nakjang Dr Helen Blair Professor Hermann Josef Vormoor Professor Olaf Heidenreich et al.	Identification of CCND2 As a RUNX1/ETO Target Required for Leukaemic Propagation	2016
Dr Deepali Pal Dr Helen Blair Dr Alex Elder Katie Dormon Dr Kate Rennie et al.	Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia	2016
Dr Alex Elder Dr Klaus Rehe Dr Simon Bomken Dr Paul Sinclair Katie Dormon et al.	The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.	2016
Dr Victoria Forster Mohammed Nahari Dr Natalia Martinez Soria Amy Bradburn Dr Sarah Fordham et al.	The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype	2016
Professor Olaf Heidenreich	UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO	2016
Dr Paul Sinclair Joanna Cheng Prahlad Raninga Rebecca Hanna Shaun Hollern et al.	A Targeted Functional Clone Tracking Assay for the Identification of Tumour Suppressor Genes in BCP- ALL Implicates the Transcription Factors FOXO3 and PRDM1	2015
Katie Dormon Elda Latif Dr Matthew Bashton Dr Deepali Pal Dr Helen Blair et al.	A Whole Genome In Vivo Crispr Screen in Primary ALL Predicts Leukaemic Relapse	2015
Judith Weiland Dr Alex Elder Dr Victoria Forster Professor Olaf Heidenreich Professor Hermann Josef Vormoor et al.	CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia	2015
Dr Klaus Rehe Dr Simon Bomken Dr Paul Sinclair Dr Lisa Russell Professor Olaf Heidenreich et al.	Childhood pre-B acute lymphoblastic leukaemia cells capable of central nervous system engraftment are common, heterogeneous and transit the blood-cerebrospinal fluid barrier	2015
Dr Frida Ponthan Professor Olaf Heidenreich Dr Kelly Coffey	Gene Silencing by RNAi in Mammalian Cells	2015
Professor Olaf Heidenreich Professor Anthony Moorman	Genomic and Drug Response Profiling of Fatal TCF3-HLF-Positive Pediatric Acute Lymphoblastic Leukaemia Identifies Recurrent Mutation Patterns and Novel Therapeutic Options	2015
Professor Olaf Heidenreich Professor Anthony Moorman	Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options	2015
Dr Alex Elder Dr Helen Blair Katie Dormon Dr Simon Bomken Dr Simon Cockell et al.	High Abundance of Acute Lymphoblastic Leukaemia Founder Clones Does Not Translate to Functional Heterogeneity	2015
Dr Lynsey McKenzie Professor Olaf Heidenreich	Identification of RUNX1/ETO Targets Required for Leukaemic Propagation	2015
Dr Natalie Bell Dr Helen Blair Lisa Price Dr Katrina Wood Professor Hermann Josef Vormoor et al.	Patient-derived xenograft and in vivo bioluminescent modelling of B-cell NHL	2015
Dr Victoria Forster Mohammed Nahari Dr Natalia Martinez Soria Amy Bradburn Hesta McNeill et al.	The Leukemia-Associated RUNX1/ETO Oncoprotein Confers a Mutator Phenotype	2015
Dr Jeyanthy Eswaran Dr Paul Sinclair Professor Olaf Heidenreich Professor Julie Irving Dr Lisa Russell et al.	The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia	2015
Dr Frida Ponthan Dr Simon Bomken Dr Deepali Pal Dr Alex Elder Hesta McNeill et al.	A Genome-Wide RNAi Screen to Identify Novel Genes Involved in Clonal Maintenance of ALL	2014
Dr Britta Vormoor Henrike Knizia Michael Batey Dr Ian Wilson Dr Petra Dildey et al.	Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging	2014
Dr Natalie Bell Dr Helen Blair Professor Hermann Josef Vormoor Dr Christopher Bacon Dr Vikki Rand et al.	Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing	2014
Dr Alex Elder Dr Simon Bomken Dr Helen Blair Professor Hermann Josef Vormoor Professor Olaf Heidenreich et al.	Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia	2014
Professor Olaf Heidenreich	Identification of a Dynamic Core Transcriptional Network in t(8;21) AML Regulating Differentiation Block and Self-Renewal	2014
Dr Daniel Williamson Professor Olaf Heidenreich	Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-Renewal	2014
Professor Olaf Heidenreich	Pontin is a critical regulator for AML1-ETO-induced leukemia	2014
Dr Simon Bomken Dr Helen Blair Professor Hermann Josef Vormoor Professor Olaf Heidenreich	Preclinical modelling of childhood acute lymphoblastic leukaemia	2014
Michael Batey Dr Frida Ponthan Dr Helen Blair Professor Olaf Heidenreich	The development and evaluation of a series of novel in vivo imaging models of AML for the assessment of drug efficacy	2014
Dr Klaus Rehe Kerrie Wilson Dr Simon Bomken Dr Daniel Williamson Professor Julie Irving et al.	Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations	2013
Marta Omedes Pujol Dan Coleman Professor Olaf Heidenreich Dr David Fulton	Determination of key structure-activity relationships in siRNA delivery with a mixed micelle system	2013
Dr Daniel Williamson Professor Olaf Heidenreich	Identification of a Dynamic Core Transcriptional Regulatory Network for t(8;21) AML	2013
Dr Simon Bomken Dr Lars Buechler Dr Klaus Rehe Dr Frida Ponthan Dr Alex Elder et al.	Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression	2013
Professor Olaf Heidenreich	Lineage-inappropriate PAX5 expression in t(8;21) acute myeloid leukemia requires signaling-mediated abrogation of polycomb repression	2013
Dr Andrea Beyerle Hesta McNeill Professor Olaf Heidenreich	Molecular Parameters of siRNA–Cell Penetrating Peptide Nanocomplexes for Efficient Cellular Delivery	2013
Professor Olaf Heidenreich Professor Hermann Josef Vormoor	The MLL recombinome of acute leukemias in 2013	2013
Michael Batey Dr Frida Ponthan Professor Olaf Heidenreich	The use of a novel in vivo orthotopic imaging model of AML for assessment of drug efficacy	2013
Dr Frederik van Delft Professor Olaf Heidenreich Professor Bryan Young	AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia	2012
Dr Andrea Beyerle Professor Olaf Heidenreich Professor James Allan	AML1/ETO Confers a Mutator Phenotype in AML	2012
Professor Olaf Heidenreich	Depletion of RUNX1/ETO in t(8:21) AML cells leads to genome-wide changes in transcription factor binding	2012
Dr Daniel Williamson Hesta McNeill Dr Michael Cullen Professor Bryan Young Professor Olaf Heidenreich et al.	Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding	2012
Dr Sebastian Prall Professor Olaf Heidenreich	Focal adhesion kinase (FAK) in t(8;21) rearranged acute myeloid leukaemia (AML)	2012
Dr Alex Elder Professor Olaf Heidenreich Professor Hermann Josef Vormoor	Lentiviralmarking as a tool to investigate the clonal complexity and evolution of ALL	2012
Dr Victoria Forster Dr Andrea Beyerle Professor Olaf Heidenreich Professor James Allan	AML1/ETO Confers a Mutator Phenotype In Acute Myeloid Leukemia Associated with Downregulation of the Base-Excision-Repair Gene OGG1	2011
Dr Klaus Rehe Professor Olaf Heidenreich Professor Hermann Josef Vormoor Beth Gibson	Central Nervous System Involvement in a Xenograft Model of Pre-B Acute Lymphoblastic Leukaemia Is Associated with Dysfunctional CXCR4 Expression and Upregulation of the Neurotropic Chemokine Receptors CCR6 and CX3CR1	2011
Professor Olaf Heidenreich	Effective and specific control of aml1/eto gene expression in acute myeloid leukemia cells by lentivector-based RNA-interference	2011
Dr Klaus Rehe Kerrie Wilson Dr Simon Bomken Professor Olaf Heidenreich Professor Hermann Josef Vormoor et al.	In acute lymphoblastic leukaemia stemness is frequent and ubiquitous	2011
Dr Simon Bomken Dr Lars Buechler Dr Klaus Rehe Dr Frida Ponthan Dr Helen Blair et al.	Lentiviral Transduction of Patient Derived Leukaemic Blasts Allowing In Vivo Bioluminescent Monitoring in An NSG Model of Leukaemia Stem Cell Maintenance	2011
Dr Frida Ponthan Hesta McNeill Dr Lars Buechler Professor Hermann Josef Vormoor Professor Olaf Heidenreich et al.	Significance of Fusion Genes for Maintenance of Leukaemia	2011
Dr Victoria Forster Amy Bradburn Professor James Allan Professor Olaf Heidenreich	The Angiogenic Factor Angiopoietin-1 Is Regulated by the Acute Myeloid Leukemia Fusion Protein AML1/ETO	2011
Professor Olaf Heidenreich	The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ET	2011
Professor Olaf Heidenreich	AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia	2010
Patricia Garrido Castro Dr Simon Bomken Elda Latif Michael Batey Hesta McNeill et al.	ANGIOPOIETIN1 a Novel Factor Implicated In MLL Rearranged Acute Lymphoblastic Leukemia and Regulated In a Fusion Gene Dependent Manner	2010
Patricia Garrido Castro Dr Simon Bomken Professor Hermann Josef Vormoor Professor Olaf Heidenreich	ANGIOPOIETIN-1 expression is modulated by leukaemic fusion genes	2010
Elda Latif Michael Batey Hesta McNeill Professor Hermann Josef Vormoor Professor Olaf Heidenreich et al.	ANGIOPOIETIN1-a Novel Factor Implicated In MLL-Rearranged Acute Lymphoblastic Leukemia and Regulated In a Fusion Gene-Dependent Manner	2010
Professor Olaf Heidenreich	EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation	2010
Dr Klaus Rehe Kerrie Wilson Dr Simon Bomken Hesta McNeill Professor Julie Irving et al.	In Acute Lymphoblastic Leukaemia, Stemness Is Frequent and Ubiquitous	2010
Dr Klaus Rehe Kerrie Wilson Dr Simon Bomken Hesta McNeill Professor Julie Irving et al.	In Acute Lymphoblastic Leukaemia, Sternness Is Frequent and Ubiquitous	2010
Dr Klaus Rehe Kerrie Wilson Dr Simon Bomken Hesta McNeill Professor Julie Irving et al.	In acute lymphoblastic leukemia, stemness is frequent and ubiquitous	2010
Dr Andreas Gessner Patricia Garrido Castro Dr Anja Scholz Professor Hermann Josef Vormoor Professor Olaf Heidenreich et al.	Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT	2010
Professor Olaf Heidenreich	Proliferation of human primary vascular smooth muscle cells depends on serum response factor	2010
Professor Olaf Heidenreich	Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6	2010
Patricia Garrido Castro Dr Anja Scholz Professor Olaf Heidenreich	Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems	2010
Dr Simon Bomken Dr Svetlana Mysina Professor Olaf Heidenreich Professor Hermann Josef Vormoor	The Germline Stem Cell Self-Renewal Gene PIWIL2 is Expressed in Both Malignant and Non-Malignant Lymphoid Cells	2010
Dr Simon Bomken Professor Hermann Josef Vormoor Professor Olaf Heidenreich	The Prosurvival Cytokine Angiopoietin-1 is Overexpressed in T(4;11)-Positive ALL and Regulated in a MLL/AF4 Dependent Manner	2010
Dr Victoria Forster Professor James Allan Professor Olaf Heidenreich	The t(8,21) Fusion Protein AML1/ETO Promotes Susceptibility to Mutation In Acute Myeloid Leukemia	2010
Dr Victoria Forster Professor James Allan Professor Olaf Heidenreich	The t(8;21) Fusion Protein AML1/ETO Promotes Susceptibility to Mutation In Acute Myeloid Leukemia	2010
Dr Simon Bomken Dr Karel Fiser Professor Olaf Heidenreich Professor Hermann Josef Vormoor	Understanding the cancer stem cell	2010
Dr Frida Ponthan Professor Olaf Heidenreich	A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO	2009
Dr Lisa Russell Professor Olaf Heidenreich Professor Anthony Moorman Professor Christine Harrison FRCPath FMedSci	A novel translocation, t(14;19)(q32;p13) involving IGHalpha and the cytokine receptor for erythropoietin	2009
Patricia Garrido Castro Dr Andreas Gessner Joachim Greiling Professor Hermann Josef Vormoor Professor Olaf Heidenreich et al.	Caspase inhibition blocks apoptosis caused by MLL-AF4 depletion in t(4;11) positive ALL cell lines, but cannot abrogate subsequent necroptosis-like cell death	2009
Dr Andreas Gessner Professor Olaf Heidenreich Professor Hermann Josef Vormoor	Caspase inhibition blocks apoptosis caused by MLL-AF4 depletion in t(4;11)-positive ALL cell lines, but cannot abrogate subsequent necroptosis-like cell death	2009
Professor Olaf Heidenreich	Chromosomal Translocation t(8;21)	2009
Dr Lisa Russell Professor Olaf Heidenreich Professor Julie Irving Professor Anthony Moorman Heather Morrison et al.	Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia	2009
Professor Olaf Heidenreich	Graft Protection in Bypass Surgery: siRNA-Mediated Silencing of Adhesion Molecules	2009
Professor Olaf Heidenreich Professor Hermann Josef Vormoor	Malignant stem cells in childhood ALL: the debate continues!	2009
Professor Olaf Heidenreich	New insights to the MLL recombinome of acute leukemias	2009
Professor Olaf Heidenreich	Targeting oncogenes with siRNAs	2009
Dr Lisa Russell Professor Anthony Moorman Professor Olaf Heidenreich Professor Christine Harrison FRCPath FMedSci	IGH@ Translocations Involving the Pseudoautosomal Region 1 (PAR1) of Both Sex Chromosomes Deregulate the Cytokine Receptor-Like Factor 2 (CRLF2) Gene in B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)	2008
Professor Olaf Heidenreich	Oligonucleotides	2008
Professor Olaf Heidenreich	Targeting myeloid precursor cells by scFv CD 33-coupled immunoliposomes in cancer therapy	2008
Dr Andreas Gessner Patricia Garrido Castro Professor Olaf Heidenreich	The t(4;11) fusion protein MLL/AF4 regulates TERT expression	2008
Professor Olaf Heidenreich	Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO	2008
Professor Olaf Heidenreich	Transient depletion of RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivo	2008
Professor Olaf Heidenreich	Epigenetic repression of the adaptor molecule LAT2 by the leukemic fusion protein AML1/ETO	2007
Professor Olaf Heidenreich	Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection	2007
Matthew Thomas Professor Olaf Heidenreich	RNA interference in haematopoietic and leukaemic cells	2007
Professor Olaf Heidenreich	siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts	2006
Professor Olaf Heidenreich	Targeting leukemic fusion proteins with small interfering RNAs: recent advances and therapeutic potentials	2006
Professor Olaf Heidenreich	Forging therapeutics from small interfering RNAs	2005
Professor Olaf Heidenreich	Gene silencing methods for mammalian cells: application of synthetic siRNAs	2005
Professor Olaf Heidenreich	Suppression of ICAM-1 in human venous endothelial cells by small interfering RNAs	2005
Professor Olaf Heidenreich	Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells	2005
Professor Olaf Heidenreich	Oncogene suppression by small interfering RNAs	2004
Professor Olaf Heidenreich	RNA interference as a potential tool in the treatment of leukaemia	2004
Professor Olaf Heidenreich	The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells	2004
Professor Olaf Heidenreich	AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells	2003
Professor Olaf Heidenreich	Gene silencing by RNAi in mammalian cells	2003
Professor Olaf Heidenreich	siRNAs: magic bullets for functional genomics and therapy?	2003
Professor Olaf Heidenreich	Specific inhibition of bcr-abl gene expression by small interfering RNA	2003
Professor Olaf Heidenreich	The apparent uptake of fluorescently labeled siRNAs by electroporated cells depends on the fluorochrome	2003
Professor Olaf Heidenreich	Analysis of the Nuclear Distribution of the Translocation t(8;21)-Derived Fusion Protein AML1/ETO by Confocal Laser Scanning Microscopy	2002
Professor Olaf Heidenreich	Serum response factor is crucial for actin cytoskeletal organization and focal adhesion assembly in embryonic stem cells	2002
Professor Olaf Heidenreich	Cleavage of AML1/MTG8 by asymmetric hammerhead ribozymes	2001
Professor Olaf Heidenreich	Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR	2001
Professor Olaf Heidenreich	Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia	2000
Professor Olaf Heidenreich	Evaluation of the effectiveness of DNA-binding drugs to inhibit transcription using the c-fos serum response element as a target	2000
Professor Olaf Heidenreich	MAPKAP kinase 2 phosphorylates serum response factor in vitro and in vivo	1999
Professor Olaf Heidenreich	Modulation of Gene Expression by Ribozymes	1999
Professor Olaf Heidenreich	Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients	1999
Professor Olaf Heidenreich	Ribozyme in der molekularen Medizin	1997
Professor Olaf Heidenreich	RNase H-independent antisense activity of oligonucleotide N3 '--> P5' phosphoramidates	1997
Professor Olaf Heidenreich	Synthetic Ribozymes: The Hammerhead Ribozyme	1997
Professor Olaf Heidenreich	A hammerhead ribozyme cleaves its target RNA during RNA preparation	1996
Professor Olaf Heidenreich	Adenovirus-mediated interferon-gamma transfer inhibits growth of transplanted HTLV-1 Tax tumors in mice	1996
Professor Olaf Heidenreich	Binding and functional effects of transcriptional factor Sp1 on the murine interleukin-6 promotor	1996
Professor Olaf Heidenreich	Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis	1996
Professor Olaf Heidenreich	Correlation of activity with stability of chemically modified ribozymes in nuclei suspension	1996
Professor Olaf Heidenreich	HAM/TSP and ATL: persistent paradoxes and new hypotheses	1996
Professor Olaf Heidenreich	Rapid PCR method for site-directed mutagenesis on double-stranded plasmid DNA	1996
Professor Olaf Heidenreich	Role of kinases in HTLV-I transformation	1996
Professor Olaf Heidenreich	Sequence requirements of ATF2 and CREB binding to the human T-cell leukemia virus type 1 LTR R region	1996
Professor Olaf Heidenreich	A new affinity purification procedure for DNA-binding proteins using bromoacetyl agarose	1995
Professor Olaf Heidenreich	Application of antisense technology to therapeutics	1995
Professor Olaf Heidenreich	Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells	1995
Professor Olaf Heidenreich	Oligonucleotides	1995
Professor Olaf Heidenreich	Ribozyme-mediated RNA degradation in nuclei suspension	1995
Professor Olaf Heidenreich	Stabilized RNA analogs for antisense and ribozyme applications	1995
Professor Olaf Heidenreich	Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding	1994
Professor Olaf Heidenreich	High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates	1994
Professor Olaf Heidenreich	Chemically modified RNA: approaches and applications	1993
Professor Olaf Heidenreich	Design of hammerhead ribozymes for the inhibition of gene expression ex vivo by exogenous application	1993
Professor Olaf Heidenreich	Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1	1992
Professor Olaf Heidenreich	Structure-function relationship of hammerhead ribozymes as probed by 2'-modifications	1991
Professor Olaf Heidenreich	Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3'-azidothymidine triphosphate	1990